Carlos Zgheib

Chief Scientific Officer at Ceria Therapeutics

Dr. Zgheib is the CSO of Ceria Thearpeutics, inc. (CeriaTx), a preclinical biotechnology company focused on developing innovative and novel therapies to treat overactive and nonproductive inflammation to promote healing. CeriaTx is developing its first product, a microRNA146a conjugated cerium oxide nanoparticle, CNP-miR146a. Under Dr. Zgheib’s leadership, CeriaTX is advancing CNP-miR146a clinical development through multiple delivery formulations for the treatment of multiple diseases including diabetic foot ulcers, burn wounds, acute lung injury, acute respiratory distress syndrome, ulcerative colitis, and myocardial infarction.

Dr. Zgheib has an expansive background in leadership and over 16 years of experience in biomedical research. He has extensive experience in regenerative medicine, tissue repair, nanotechnology, and biomaterials. Dr. Zgheib has overseen the development of CNP-miR146a, a combination of cerium oxide nanoparticles (CNPs) that possess ROS scavenging properties conjugated with a miR-146a mimetic, an anti-inflammatory molecule. This novel strategy allows to synergistically target oxidative stress and inflammation. Dr. Zgheib earned a Doctor of Philosophy Degree in Medical Pharmacology and Toxicology with an emphasis on targeting inflammation to promote tissue repair and regeneration. Dr. Zgheib also earned a Master of Pharmacology and Cosmetology Degree, a Master of Biomedical Sciences Degree, and a Bachelor of Biochemistry Degree. Dr. Zgheib trained at the Sanford Burnham Prebys Medical Discovery Institute where he studied regenerative medicine with an emphasis on elucidating the regulatory mechanisms of inflammation and oxidative stress in injured tissue, and identifying potential therapeutic approaches that target these processes to promote tissue repair and healing. Dr. Zgheib is a well published author and has multiple US and International patents to his name. Dr. Zgheib received many awards including The 2018 Owen H. Wangensteen Excellence in Research Award from The American College of Surgeons, the 2019 Wound Healing Society Shark Tank Finalist, and the Award for Academic Excellence and Superior Scholarship from The Honor Society of Phi Kappa Phi.

Links

Previous companies

Nemours logo

Timeline

  • Chief Scientific Officer

    May, 2020 - present